TY - JOUR T1 - Severe acquired hypertriglyceridemia following COVID-19 JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2021-246698 VL - 14 IS - 11 SP - e246698 AU - Lauré M Fijen AU - Aldo Grefhorst AU - Johannes H M Levels AU - Danny M Cohn Y1 - 2021/11/01 UR - http://casereports.bmj.com/content/14/11/e246698.abstract N2 - Severe hypertriglyceridemia is a major risk factor for acute pancreatitis. In exceptional cases, it is caused by plasma components inhibiting lipoprotein lipase activity. This phenomenon is predominantly associated with autoimmune diseases. Here, we report a case of severe hypertriglyceridemia due to a transient reduction in lipoprotein lipase activity following an episode of COVID-19 in an otherwise healthy 45-year-old woman. The lipoprotein lipase activity of the patient was markedly reduced compared with a healthy control and did recover to 20% of the healthy control’s lipoprotein lipase activity 5 months after the COVID-19 episode. Mixing tests substantiated reduced lipolytic capacity in the presence of the patient’s plasma at presentation compared with a homozygous lipoprotein lipase-deficient control, which was no longer present at follow-up. Western blotting confirmed that the quantity of lipoprotein lipase was not aberrant. Fibrate treatment and a strict hypolipidemic diet improved the patient’s symptoms and triglyceride levels. ER -